Apella Capital
UTHR icon

Apella Capital’s United Therapeutics UTHR Stock Holding History

Apella Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$246K Buy
451
+96
+27% +$49.6K ﹤0.01% 686
2026
Q2 		$200K Buy
355
+11
+3% +$6.2K ﹤0.01% 676
2026
Q1 		$202K Buy
+344
New +$171K ﹤0.01% 647

Other funds holding UTHR

Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.2B AUM 25.19% 1-Year Est. Return

Apella Capital's UTHR Position: Q3 2026 in Review

Apella Capital increased its United Therapeutics (UTHR) stake by 27% in Q3 2026, buying an estimated $49.6K and bringing the position to 451 shares worth $246K. The position accounts for ﹤0.01% of the portfolio, ranked #686.

Apella Capital first reported a position in UTHR in Q1 2026 and has held it in 3 quarters since. 390 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.

  • Apella Capital held 451 shares of United Therapeutics worth $246K as of Q3 2026.
  • Apella Capital bought 96 United Therapeutics shares in Q3 2026, an estimated $49.6K.
  • United Therapeutics made up ﹤0.01% of Apella Capital's portfolio in Q3 2026, its #686 holding.
  • Apella Capital first reported a position in United Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 390 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.

Based on Apella Capital's 13F filing for Q3 2026, filed 8 Oct 2026.